These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11595884)

  • 21. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypercalcemia and malignant melanoma.
    Burt ME; Brennan MF
    Am J Surg; 1979 Jun; 137(6):790-4. PubMed ID: 453473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parathyroid hormone related protein and hypercalcaemia in breast cancer.
    Bundred NJ; Ratcliffe WA; Walker RA; Coley S; Morrison JM; Ratcliffe JG
    BMJ; 1991 Dec; 303(6816):1506-9. PubMed ID: 1782489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
    Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
    Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The bone isoenzyme of alkaline phosphatase in hypercalcaemic cancer patients.
    Body JJ; Dumon JC; Blocklet D; Darte C
    Eur J Cancer; 1997 Sep; 33(10):1578-82. PubMed ID: 9389918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
    Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
    Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTH-independent hypercalcaemia and non-melanoma skin cancer.
    Nicolae I; Schipor S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):449-52. PubMed ID: 19778357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Melanoma and primary hyperparathyroidism].
    Maerens-Tchokokam B; Bailly N; Collet E; Dalac S; Rat P; Lambert D
    Ann Dermatol Venereol; 1993; 120(3):215-7. PubMed ID: 8239359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.
    Ralston SH; Fogelman I; Gardiner MD; Boyle IT
    Br Med J (Clin Res Ed); 1984 May; 288(6428):1405-8. PubMed ID: 6426577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of malignant hypercalcaemia.
    Hurtado J; Esbrit P
    Expert Opin Pharmacother; 2002 May; 3(5):521-7. PubMed ID: 11996631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ; Bijvoet OL; van Oosterom AT
    Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
    Ling PJ; A'Hern RP; Hardy JR
    Br J Cancer; 1995 Jul; 72(1):206-9. PubMed ID: 7599053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD
    Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
    Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
    Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment.
    Gibbs CJ; Peacock M
    Postgrad Med J; 1986 Oct; 62(732):937-8. PubMed ID: 3774726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bone metastases: pathogenesis and treatment with diphosphonates].
    Body JJ
    Bull Mem Acad R Med Belg; 1997; 152(3):169-74; discussion 174-6. PubMed ID: 9491638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.